Oxytocin Modulates Eye Gaze Behavior During Social Processing
1 other identifier
interventional
40
1 country
2
Brief Summary
The main aim of the study is to examine whether the effects of intranasal oxytocin on eye-gaze behavior towards social stimuli are modulated via individual differences in trait autism
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable healthy
Started Jun 2017
Longer than P75 for not_applicable healthy
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 9, 2017
CompletedFirst Submitted
Initial submission to the registry
September 20, 2017
CompletedFirst Posted
Study publicly available on registry
September 26, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2019
CompletedOctober 29, 2018
October 1, 2018
2.1 years
September 20, 2017
October 26, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Global eye gaze characteristic: differences between oxytocin and placebo treatment
Global eye-gaze patterns will be compared between the administration of oxytocin and placebo
45-90 minutes after treatment administration
Feature-specific eye gaze characteristics: differences between oxytocin and placebo treatment
Localized feature-specific eye gaze patterns will be compared between oxytocin and placebo treatment
45-90 minutes after treatment administration
Secondary Outcomes (2)
Global eye gaze characteristic - associations with autism traits
45-90 minutes after treatment administration
Feature-specific eye gaze characteristics - associations with trait autism
45-90 minutes after treatment administration
Study Arms (2)
Order of administration: oxytocin - placebo
EXPERIMENTALParticipants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
Order of administration: placebo - oxytocin
EXPERIMENTALParticipants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
Interventions
24 IU of oxytocin nasal spray will be applied to each subject.
24 IU of of placebo nasal spray will be applied to each subject.
Eligibility Criteria
You may qualify if:
- Healthy subjects without any past or present psychiatric or neurological disorders
You may not qualify if:
- History of brain injury
- Visual impairments
- Use of medication
- Contraindications for oxytocin administration
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
school of life science and technology, University of Electronic Science and Technology of China
Chengdu, Sichuan, 610054, China
University of Electronic Science and Technology of China
Chengdu, Sichuan, 611731, China
Related Publications (1)
Le J, Kou J, Zhao W, Fu M, Zhang Y, Becker B, Kendrick KM. Oxytocin Facilitation of Emotional Empathy Is Associated With Increased Eye Gaze Toward the Faces of Individuals in Emotional Contexts. Front Neurosci. 2020 Aug 11;14:803. doi: 10.3389/fnins.2020.00803. eCollection 2020.
PMID: 32848571DERIVED
Study Officials
- STUDY CHAIR
Juan Kou, MSc
University of Electronic Science and Technology of China
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
September 20, 2017
First Posted
September 26, 2017
Study Start
June 9, 2017
Primary Completion
July 1, 2019
Study Completion
July 1, 2019
Last Updated
October 29, 2018
Record last verified: 2018-10